- Home
- / Galectin Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Galectin Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.5
2024-10-28
Market Capitalization
$155.1 M
2024-10-28
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 6.9M | 5.4M | 6.4M | 7.0M | 7.0M | 6.2M | 4.5M | 7.1M | 6.0M | 5.5M | 6.4M | 6.6M | 5.9M | 5.9M | 5.8M |
| Operating expense total | 10.4M | 9.9M | 12.1M | 15.4M | 20.1M | 21.5M | 16.2M | 13.6M | 13.4M | 23.4M | 38.4M | 38.1M | 42.4M | 20.1M | |
| EBIT | (10.4M) | (9.9M) | (12.1M) | (15.4M) | (20.1M) | (21.5M) | (16.2M) | (13.6M) | (13.4M) | (23.4M) | (30.2M) | (38.4M) | (38.1M) | (42.4M) | (20.1M) |
| Interest income | 18.0K | 24.0K | 16.0K | 42.0K | 52.0K | 45.0K | 24.0K | 38.0K | 231.0K | 66.0K | 3.0K | 52.0K | 230.0K | 338.0K | 126.0K |
| Interest expense | 506.0K | 224.0K | 45.0K | 12.0K | 298.0K | 2.8M | |||||||||
| Net Income | (10.9M) | (9.7M) | (12.1M) | (15.8M) | (20.0M) | (21.4M) | (16.2M) | (13.9M) | (13.3M) | (23.5M) | (30.5M) | (38.8M) | (41.1M) | (47.0M) | (30.8M) |
| EPS | (0.6) | (0.7) | (0.8) | (0.5) |